Izvorni znanstveni članak

Effect of Statin Therapy Duration on Bone Turnover Markers in Dyslipidemic Patients

OLGA CVIJANOVIĆ ; Department of Anatomy, Medical Faculty of Rijeka, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia
NENAD BIĆANIĆ ; Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Hospital Rijeka, Medical Faculty of University of Rijeka, Croatia
ŽELJKA CRNČEVIĆ ORLIĆ ; Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Hospital Rijeka, Medical Faculty of University of Rijeka, Croatia
SANJA KLOBUČAR MAJANOVIĆ ; Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Hospital Rijeka, Medical Faculty of University of Rijeka, Croatia
TAMARA TURK WENSVEEN ; Department of Endocrinology, Diabetes and Metabolic Diseases, Clinical Hospital Rijeka, Medical Faculty of University of Rijeka, Croatia
IVAN BUBIĆ ; Department of Nephrology, Clinical Hospital Rijeka, Medical Faculty of University of Rijeka, Croatia

Sažetak

Background and Purpose: Statins are cholesterol-lowering drugs decreasing bone resorption by inhibition of the farnesyl diphosphate synthase step in the mevalonic acid pathway and therefore are believed to have beneficial effects on bone status. The objective was to examine the relationship between statin therapy duration and bone turnover markers in dyslipidemic patients.

Patients and Methods: Two hundred and eighty subjects were divided
into five groups depending on duration of statin therapy: (controls 0 yrs); (0.1-1.5 yrs); (2-5 yrs); (6-10 yrs); (11-30 yrs). ELISA method was applied on fasting serums using bone formation markers: Osteoprotegerin (pmol/l) and Osteocalcin (ng/ml) and bone resorption markers: sRANKL (pmol/l) and CrossLaps (ng/ml). In statistical analysis, multiple regressions were used.

Results: A common influence of studied predictor variables was statistically significant for sRANKL, Serum CrossLaps and osteocalcin (P<0.001), while statistical significance was not found for osteoprotegerin. The largest shares of contributions were recorded in Model 2 for the statin group (40%) and BMI (36%) and in Model 1 for statin group (35%) and total cholesterol (28%).

Conclusions: Statins showed favorable influence on osteocalcin and
sRANKL, indicating improved bone metabolism in patients with longer duration of statin therapy.

Ključne riječi

Hrčak ID:

139525

URI

https://hrcak.srce.hr/139525

Datum izdavanja:

31.3.2015.

Posjeta: 1.201 *